Abstract: |
In 1865, Armand Trousseau was the first to systemically describe the connection between thrombosis and cancer through autopsy studies.The risk of venous thromboembolism (VTE) in cancer is far better described in comparison to arterial thrombosis in cancer patients. However, with increased cancer survival and novel vascular targeted cancer therapies, arterial thromboembolic events (ATE) have been increasingly reported. An individual’s ATE risk is a combination of personal risk factors, cancer characteristics, and vascular toxicity of therapy. Nonbacterial thrombotic endocarditis (NBTE) is another mechanism of ATE frequently seen in cancer patients.The occurrence of ATE almost always interrupts cancer treatment and negatively affects outcomes. Clinical cases of ATE, including NBTE, due to cancer characteristics, treatment and personal risk factors are presented. © Springer Nature Switzerland AG 2021 R. M. Steingart et al. (eds.). |